Logo image of NBIX

NEUROCRINE BIOSCIENCES INC (NBIX) Stock Fundamental Analysis

NASDAQ:NBIX - Nasdaq - US64125C1099 - Common Stock - Currency: USD

153.29  +2.61 (+1.73%)

After market: 153.29 0 (0%)

Fundamental Rating

8

NBIX gets a fundamental rating of 8 out of 10. The analysis compared the fundamentals against 572 industry peers in the Biotechnology industry. Both the health and profitability get an excellent rating, making NBIX a very profitable company, without any liquidiy or solvency issues. NBIX has both an excellent growth and valuation score. This means it is growing and it is still cheap. This is a rare combination! These ratings could make NBIX a good candidate for value and growth and quality investing.


Dividend Valuation Growth Profitability Health

Quickly go to:

9

1. Profitability

1.1 Basic Checks

NBIX had positive earnings in the past year.
NBIX had a positive operating cash flow in the past year.
In the past 5 years NBIX has always been profitable.
NBIX had a positive operating cash flow in each of the past 5 years.
NBIX Yearly Net Income VS EBIT VS OCF VS FCFNBIX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 100M -100M 200M 300M 400M

1.2 Ratios

NBIX has a better Return On Assets (10.92%) than 96.46% of its industry peers.
NBIX has a Return On Equity of 14.19%. This is amongst the best in the industry. NBIX outperforms 96.28% of its industry peers.
With an excellent Return On Invested Capital value of 13.96%, NBIX belongs to the best of the industry, outperforming 96.99% of the companies in the same industry.
The Average Return On Invested Capital over the past 3 years for NBIX is below the industry average of 13.83%.
The 3 year average ROIC (9.89%) for NBIX is below the current ROIC(13.96%), indicating increased profibility in the last year.
Industry RankSector Rank
ROA 10.92%
ROE 14.19%
ROIC 13.96%
ROA(3y)6.18%
ROA(5y)8.97%
ROE(3y)8.92%
ROE(5y)13.75%
ROIC(3y)9.89%
ROIC(5y)11.96%
NBIX Yearly ROA, ROE, ROICNBIX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 20 -20 -40

1.3 Margins

With an excellent Profit Margin value of 17.21%, NBIX belongs to the best of the industry, outperforming 96.46% of the companies in the same industry.
In the last couple of years the Profit Margin of NBIX has grown nicely.
Looking at the Operating Margin, with a value of 26.23%, NBIX belongs to the top of the industry, outperforming 97.17% of the companies in the same industry.
NBIX's Operating Margin has improved in the last couple of years.
With an excellent Gross Margin value of 98.52%, NBIX belongs to the best of the industry, outperforming 97.70% of the companies in the same industry.
NBIX's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM 26.23%
PM (TTM) 17.21%
GM 98.52%
OM growth 3Y-12.58%
OM growth 5Y20.67%
PM growth 3Y-30.22%
PM growth 5Y23.12%
GM growth 3Y-0.38%
GM growth 5Y-0.21%
NBIX Yearly Profit, Operating, Gross MarginsNBIX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -200 -400 -600 -800

More info and screens

8

2. Health

2.1 Basic Checks

The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so NBIX is still creating some value.
NBIX has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, NBIX has more shares outstanding
NBIX has a better debt/assets ratio than last year.
NBIX Yearly Shares OutstandingNBIX Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M 80M
NBIX Yearly Total Debt VS Total AssetsNBIX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 1B 2B 3B

2.2 Solvency

An Altman-Z score of 12.92 indicates that NBIX is not in any danger for bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 12.92, NBIX belongs to the top of the industry, outperforming 88.85% of the companies in the same industry.
NBIX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Altman-Z 12.92
ROIC/WACC1.3
WACC10.73%
NBIX Yearly LT Debt VS Equity VS FCFNBIX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 500M 1B 1.5B 2B

2.3 Liquidity

NBIX has a Current Ratio of 4.37. This indicates that NBIX is financially healthy and has no problem in meeting its short term obligations.
NBIX has a Current ratio (4.37) which is in line with its industry peers.
A Quick Ratio of 4.26 indicates that NBIX has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 4.26, NBIX is in line with its industry, outperforming 50.27% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 4.37
Quick Ratio 4.26
NBIX Yearly Current Assets VS Current LiabilitesNBIX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 500M 1B 1.5B

More info and screens

9

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 100.54% over the past year.
NBIX shows a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 70.09% yearly.
Looking at the last year, NBIX shows a very strong growth in Revenue. The Revenue has grown by 25.72%.
NBIX shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 33.13% yearly.
EPS 1Y (TTM)100.54%
EPS 3Y23.01%
EPS 5Y70.09%
EPS Q2Q%51.22%
Revenue 1Y (TTM)25.72%
Revenue growth 3Y21.74%
Revenue growth 5Y33.13%
Sales Q2Q%24.72%

3.2 Future

NBIX is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 47.17% yearly.
Based on estimates for the next years, NBIX will show a quite strong growth in Revenue. The Revenue will grow by 17.34% on average per year.
EPS Next Y73.49%
EPS Next 2Y60.22%
EPS Next 3Y53.84%
EPS Next 5Y47.17%
Revenue Next Year24.55%
Revenue Next 2Y21.19%
Revenue Next 3Y19.97%
Revenue Next 5Y17.34%

3.3 Evolution

The estimated forward EPS growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
NBIX Yearly Revenue VS EstimatesNBIX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 1B 2B 3B 4B 5B
NBIX Yearly EPS VS EstimatesNBIX Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 5 10 15 20

More info and screens

8

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings ratio is 41.10, which means the current valuation is very expensive for NBIX.
Based on the Price/Earnings ratio, NBIX is valued cheaper than 94.34% of the companies in the same industry.
When comparing the Price/Earnings ratio of NBIX to the average of the S&P500 Index (28.51), we can say NBIX is valued slightly more expensively.
With a Price/Forward Earnings ratio of 24.68, NBIX is valued on the expensive side.
93.63% of the companies in the same industry are more expensive than NBIX, based on the Price/Forward Earnings ratio.
When comparing the Price/Forward Earnings ratio of NBIX to the average of the S&P500 Index (93.88), we can say NBIX is valued rather cheaply.
Industry RankSector Rank
PE 41.1
Fwd PE 24.68
NBIX Price Earnings VS Forward Price EarningsNBIX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60 80

4.2 Price Multiples

Based on the Enterprise Value to EBITDA ratio, NBIX is valued cheaply inside the industry as 95.58% of the companies are valued more expensively.
Based on the Price/Free Cash Flow ratio, NBIX is valued cheaply inside the industry as 95.22% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF 35.27
EV/EBITDA 21.42
NBIX Per share dataNBIX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 5 10 15 20 25

4.3 Compensation for Growth

The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
The excellent profitability rating of NBIX may justify a higher PE ratio.
NBIX's earnings are expected to grow with 53.84% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.56
PEG (5Y)0.59
EPS Next 2Y60.22%
EPS Next 3Y53.84%

More info and screens

0

5. Dividend

5.1 Amount

NBIX does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

NEUROCRINE BIOSCIENCES INC

NASDAQ:NBIX (1/30/2025, 7:34:54 PM)

After market: 153.29 0 (0%)

153.29

+2.61 (+1.73%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)10-30 2024-10-30/bmo
Earnings (Next)02-11 2025-02-11/amc
Inst Owners95.13%
Inst Owner Change0.08%
Ins Owners0.98%
Ins Owner Change-1.08%
Market Cap15.52B
Analysts83.64
Price Target168.26 (9.77%)
Short Float %3.36%
Short Ratio3.26
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-29.39%
Min EPS beat(2)-41.42%
Max EPS beat(2)-17.35%
EPS beat(4)1
Avg EPS beat(4)-23.67%
Min EPS beat(4)-59.17%
Max EPS beat(4)23.28%
EPS beat(8)2
Avg EPS beat(8)-101.77%
EPS beat(12)2
Avg EPS beat(12)-94.57%
EPS beat(16)4
Avg EPS beat(16)-71.78%
Revenue beat(2)2
Avg Revenue beat(2)3.77%
Min Revenue beat(2)1.54%
Max Revenue beat(2)5.99%
Revenue beat(4)2
Avg Revenue beat(4)0.91%
Min Revenue beat(4)-2.58%
Max Revenue beat(4)5.99%
Revenue beat(8)4
Avg Revenue beat(8)0.79%
Revenue beat(12)7
Avg Revenue beat(12)1.02%
Revenue beat(16)8
Avg Revenue beat(16)-0.07%
PT rev (1m)1.15%
PT rev (3m)-1.76%
EPS NQ rev (1m)0%
EPS NQ rev (3m)26.77%
EPS NY rev (1m)0%
EPS NY rev (3m)-10.03%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)7.71%
Revenue NY rev (1m)0.08%
Revenue NY rev (3m)0.97%
Valuation
Industry RankSector Rank
PE 41.1
Fwd PE 24.68
P/S 6.92
P/FCF 35.27
P/OCF 32.58
P/B 5.71
P/tB 5.78
EV/EBITDA 21.42
EPS(TTM)3.73
EY2.43%
EPS(NY)6.21
Fwd EY4.05%
FCF(TTM)4.35
FCFY2.84%
OCF(TTM)4.71
OCFY3.07%
SpS22.15
BVpS26.85
TBVpS26.51
PEG (NY)0.56
PEG (5Y)0.59
Profitability
Industry RankSector Rank
ROA 10.92%
ROE 14.19%
ROCE 18.95%
ROIC 13.96%
ROICexc 23.1%
ROICexgc 23.53%
OM 26.23%
PM (TTM) 17.21%
GM 98.52%
FCFM 19.62%
ROA(3y)6.18%
ROA(5y)8.97%
ROE(3y)8.92%
ROE(5y)13.75%
ROIC(3y)9.89%
ROIC(5y)11.96%
ROICexc(3y)24.26%
ROICexc(5y)27.99%
ROICexgc(3y)25.18%
ROICexgc(5y)28.55%
ROCE(3y)13.42%
ROCE(5y)18.4%
ROICexcg growth 3Y6.34%
ROICexcg growth 5Y29.41%
ROICexc growth 3Y4.71%
ROICexc growth 5Y28.22%
OM growth 3Y-12.58%
OM growth 5Y20.67%
PM growth 3Y-30.22%
PM growth 5Y23.12%
GM growth 3Y-0.38%
GM growth 5Y-0.21%
F-Score8
Asset Turnover0.63
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Debt/EBITDA 0
Cap/Depr 141.25%
Cap/Sales 1.62%
Interest Coverage 168.09
Cash Conversion 77.59%
Profit Quality 114.05%
Current Ratio 4.37
Quick Ratio 4.26
Altman-Z 12.92
F-Score8
WACC10.73%
ROIC/WACC1.3
Cap/Depr(3y)151.1%
Cap/Depr(5y)155.21%
Cap/Sales(3y)1.56%
Cap/Sales(5y)1.52%
Profit Quality(3y)204.66%
Profit Quality(5y)207.75%
High Growth Momentum
Growth
EPS 1Y (TTM)100.54%
EPS 3Y23.01%
EPS 5Y70.09%
EPS Q2Q%51.22%
EPS Next Y73.49%
EPS Next 2Y60.22%
EPS Next 3Y53.84%
EPS Next 5Y47.17%
Revenue 1Y (TTM)25.72%
Revenue growth 3Y21.74%
Revenue growth 5Y33.13%
Sales Q2Q%24.72%
Revenue Next Year24.55%
Revenue Next 2Y21.19%
Revenue Next 3Y19.97%
Revenue Next 5Y17.34%
EBIT growth 1Y69.1%
EBIT growth 3Y6.43%
EBIT growth 5Y60.65%
EBIT Next Year128.88%
EBIT Next 3Y59.34%
EBIT Next 5Y45.47%
FCF growth 1Y148.64%
FCF growth 3Y18.45%
FCF growth 5Y36.4%
OCF growth 1Y137.49%
OCF growth 3Y19.5%
OCF growth 5Y30.91%